BlackThorn
is a biopharmaceutical company that discovers and develops novel targeted therapeutics for the treatment of neurobehavioral disorders... Read moreBlackThorn
is a biopharmaceutical company that discovers and develops novel targeted therapeutics for the treatment of neurobehavioral disorders... Read more
News
Jan 23, 2020
MarketScreener
BlackThorn: BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders
Dec 11, 2019
Associated Press News
BlackThorn: BlackThorn Therapeutics Reports Data Supporting Phase 2 Development of KOR Antagonist, BTRX-335140, in Depression and Other CNS Disorders
Oct 23, 2019
BioPortfolio
BlackThorn: BlackThorn Therapeutics Reports New Insights into Neurobehavioral Disorders at the 49th Annual Meeting of the Society for Neuroscience
Oct 21, 2019
MarketScreener
BlackThorn: BlackThorn Therapeutics Appoints William J. Martin, Ph.D., as Chief Executive Officer to Lead Next Stage of Growth
Jul 23, 2019
Outsourcing-Pharma
BlackThorn: Consortium creates a 'behavioral biomarker' through AI models
Apr 01, 2019
BioPortfolio
BlackThorn: BlackThorn Therapeutics Announces Positive Phase 1 Results for Its Selective KOR Antagonist BTRX335140
Mar 04, 2019
PR Newswire
Press Release: BlackThorn : BlackThorn Therapeutics and Total Brain Announce Exclusive License Agreement to Enhance Patient Selection and Development of Targeted Therapies for Neurobehavioral Disorders
Jan 04, 2019
4-traders
BlackThorn: BlackThorn Therapeutics : Announces R&D Updates
Aug 06, 2018
firstwordpharma
BlackThorn: BlackThorn Therapeutics Announces Exclusive Licensing Agreement and Extension of Key Collaboration With Yale University
Jul 29, 2018
BioPortfolio
BlackThorn: Blackthorn Therapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 13042018 Prices from USD $250
BlackThorn Competitors
1
2
3
4
5
6
7
8
9
10